SG Americas Securities LLC Decreases Position in Amneal Pharmaceuticals, Inc. $AMRX

SG Americas Securities LLC decreased its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 9.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 710,876 shares of the company’s stock after selling 73,927 shares during the period. SG Americas Securities LLC’s holdings in Amneal Pharmaceuticals were worth $8,836,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also modified their holdings of the stock. Vanguard Group Inc. grew its stake in Amneal Pharmaceuticals by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 17,954,973 shares of the company’s stock worth $179,729,000 after purchasing an additional 403,582 shares in the last quarter. Rubric Capital Management LP boosted its stake in shares of Amneal Pharmaceuticals by 5.3% in the 3rd quarter. Rubric Capital Management LP now owns 12,334,941 shares of the company’s stock valued at $123,473,000 after buying an additional 624,609 shares during the period. Dimensional Fund Advisors LP grew its position in shares of Amneal Pharmaceuticals by 3.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,609,040 shares of the company’s stock worth $70,681,000 after buying an additional 177,906 shares in the last quarter. Morgan Stanley increased its stake in shares of Amneal Pharmaceuticals by 37.5% during the fourth quarter. Morgan Stanley now owns 4,818,099 shares of the company’s stock worth $60,708,000 after buying an additional 1,315,018 shares during the period. Finally, Nantahala Capital Management LLC raised its holdings in Amneal Pharmaceuticals by 14.7% in the second quarter. Nantahala Capital Management LLC now owns 4,367,438 shares of the company’s stock valued at $35,333,000 after acquiring an additional 558,877 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have commented on AMRX shares. Truist Financial increased their price objective on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Barclays increased their target price on Amneal Pharmaceuticals from $15.00 to $16.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Zacks Research downgraded Amneal Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, April 6th. UBS Group started coverage on Amneal Pharmaceuticals in a report on Friday, April 17th. They issued a “buy” rating and a $19.00 price objective on the stock. Finally, Wall Street Zen raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, June 21st. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.80.

Amneal Pharmaceuticals Price Performance

NASDAQ AMRX opened at $17.23 on Friday. The company has a fifty day moving average of $13.82 and a two-hundred day moving average of $13.40. The company has a market capitalization of $5.50 billion, a PE ratio of 45.34 and a beta of 1.30. Amneal Pharmaceuticals, Inc. has a 1 year low of $7.66 and a 1 year high of $17.86.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its earnings results on Thursday, May 7th. The company reported $0.27 earnings per share for the quarter. The business had revenue of $722.52 million during the quarter. Amneal Pharmaceuticals had a negative return on equity of 313.96% and a net margin of 4.01%. On average, research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.92 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In other news, Director Deborah M. Autor sold 34,819 shares of the stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $12.94, for a total value of $450,557.86. Following the completion of the sale, the director directly owned 93,660 shares of the company’s stock, valued at approximately $1,211,960.40. This represents a 27.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 17.30% of the company’s stock.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.